CClinicalTrials.gg
Active, not recruitingNCT05531370EmBRAiZUpdated Jul 2, 2026

Implementation of Evidence-based Breathing Retraining for Patients With Asthma in Region Zealand

An interventional study of Breathing Retraining in Asthma, sponsored by Naestved Hospital. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Naestved Hospital · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to implement the evidence-based intervention breathing retraining into clinical care of patients with symptomatic asthma irrespective of asthma severity or comorbidities, and in a diverse multicentre setting to evaluate implementation outcomes. This will meet patients' needs and improve health and life situation in patients with uncontrolled asthma. Further, the study will evaluate implementation outcomes.

Read the detailed description

This study is a hybrid-designed prospective multicenter implementation evaluation study, in which the investigators secondarily will maintain measuring effectiveness of breathing retraining in a real-world setting including primary and secondary health care and add cross-sectorial co-operation. Thus, investigators include more primary outcomes.

The study is part of Exercise First-project, a collaboration of The National Health Service, Region Zealand and the research unit PROgrez, Department of Physiotherapy and Occupational Therapy at Næstved, Slagelse, Ringsted hospitals.

02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Implementation
  • Asthma
  • Breathing Retraining
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Doctor diagnosed asthma;
  • Incompletely controlled asthma or worse: Asthma Control Questionnaire (ACQ5) score ≥0.8;
  • Residence (or asthma treatment program) in Region Zealand, Denmark;
  • Able to read and understand Danish or available assistance to help understand information material, intervention content and respond to questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Unwilling to participate;
  • Unable to participate in the intervention due to physical or mental condition.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Breathing Retraining (BR)

    Patients will receive three sessions (60 min, 30 min, 30 min) of breathing retraining (BR), 1-to-1 with a trained physiotherapist. As preferred by the patient: * Hybrid delivery mode of BR (H-BR): First session on-site at hospital/clinic for initial assessment and introduction, and following sessions online (MedComs VDX platform or equal; participants access using web cam and sound on smart phone, tablet, or pc). * Ordinary delivery of BR: Three sessions on-site at hospital/clinic.

    Other: Breathing Retraining

Interventions

  • OtherBreathing Retraining

    Conforming the real-world setting, all participants will continue standard asthma care, i.e., acute and planned visits at GP or pulmonologist. BR aims to normalize the inhaled volume, nasal inhalation, exhalation to the resting position of the chest (functional residual capacity, FRC), use of the diaphragm muscle, and to move lower parts of the chest in a frequency of 12-16 per minute. This pattern is initially trained in rest (e.g., side lying or sitting), then during physical activity (e.g., walking). Uncontrolled coughing, frequent yawning or sighing is handled by a suppression technique. Relaxation technique is introduced as a separate activity but to be combined with the breathing pattern method to be used in both resting and as possible during physical activity.

    Also known as: Breathing Exercises

05

What researchers measure

Primary outcomes

  1. Adoption of intervention (Uptake)

    Organization-related (Pulmonologists, general practioners, physiotherapists) outcome: Proportion of general practices and of hospitals that will adopt BR.

    Time frame: Through study completion, an average of 1 year

  2. Implementation of intervention (Fidelity)

    Organization-related (physiotherapists) outcome: % of contents delivered as planned assessed by a checklist of key aspects in the breathing retraining-intervention.

    Time frame: Through study completion, an average of 1 year

  3. Feasibility of online sessions in Hybrid delivery mode of BR (H-BR) (Acceptability)

    Patient- and Organization-related (physiotherapists) outcome: assessed by a semi-structured interview.

    Time frame: Through study completion, an average of 1 year

  4. Effectiveness: MiniAsthma Quality of Life Questionnaire, MiniAQLQ

    Patient-related outcome, disease specific quality of life questionnaire. 7-point Likert scales from 1-7, 1 = worse outcome, 7 = better outcome. Success rates of improvements minus deteriorations of individual effects, measured at 12 month follow up.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. MiniAsthma Quality of Life Questionnaire, MiniAQLQ

    Patient-related outcome: Mean of disease specific quality of life questionnaire. 7-point Likert scales from 1-7, 1 = worse outcome, 7 = better outcome.

    Time frame: Change from baseline to 12 months

  2. Breathing pattern observation

    Patient-related outcome. Pre-defined key aspects of the breathing pattern assessed qualitatively observation by the physiotherapist.

    Time frame: Change from baseline to 12 month

  3. Objective physical activity level

    Patient-related outcome. Objectively measured physical activity and inactivity using combined wearable thigh and wrist accelerometers, worn for seven consecutive days.

    Time frame: Change from baseline to 12 month

  4. Objective steps per day (average)

    Patient-related outcome. Objectively measured steps per day using combined wearable thigh and wrist accelerometers, worn for seven consecutive days.

    Time frame: Change from baseline to 12 month

Other outcomes

  1. Ashma severity by Global Initiative for Asthma (GINA) treatment steps

    Patient-related outcome. Asthma severity assessed by pharmacotherapy level, calculated into GINA treatment steps 1-5 (1 = mild asthma, 5 = severe asthma), using a questionnaire completed by the physiotherapist during an interview with the patient.

    Time frame: Change from baseline to 12 month

  2. Adverse events (Safety)

    Patient-related outcome; number, % caused discontinuation.

    Time frame: Post-intervention (3-month)

  3. Asthma Control Questionnaire, ACQ5

    Patient-related outcome: ACQ5 i.e. item 1-5 of the ACQ. Mean of asthma symptom level questionnaire; 7-point Likert scales from 0-6, 0 = better outcome, 6 = worse outcome.

    Time frame: Change from baseline to 12 month

  4. Number of online sessions delivered

    Number, % of total sessions.

    Time frame: Post-intervention (3-month)

06

Study locations

1 site
  • Naestved Hospital
    Næstved, Region Sjælland 4700, Denmark
07

References and documents

Study documents

  • Study protocol · Apr 1, 2024
  • Statistical analysis plan · Jun 19, 2026

Documents are hosted by the registry — open the source record to download them.

08

Registry details

Key details

Study ID
NCT05531370
Lead sponsor
Naestved Hospital
Responsible party
Sponsor
First posted
Sep 7, 2022
Start date
Jun 30, 2022
Primary completion
Dec 31, 2025
Completion
Dec 31, 2026 (estimated)
Last update
Jul 2, 2026

Study contacts

Søren T Skou, Prof.
study chair · Naestved-Slagelse-Ringsted Hospitals; University of Southern Denmark
Lars H Tang, Assoc.Prof.
study chair · Naestved-Slagelse-Ringsted Hospitals; University of Southern Denmark
Cecilie L Egholm, PostDoc.
study chair · Naestved-Slagelse-Ringsted Hospitals, Denmark
Uffe Bodtger, Prof.
study chair · Zealand University Hospital; University of Southern Denmark
Mike Thomas, Prof.
study chair · Primary Care Research University of Southampton, UK
Karen H Andreasson, Dr.
principal investigator · Naestved-Slagelse-Ringsted Hospitals; University of Southern Denmark

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion